Clues From Strange New Antigens: How Skin Responds to Nonself

Skin is both the most immunogenic transplantable tissue and the easiest to observe clinically, making it an ideal system for understanding alloreactivity. We trace the concept of alloantigens from early transfusion work and the discovery of ABO and major histocompatibility complex/human leukocyte antigen to contemporary lessons learned by treating skin as both clinical grafts and experimental models. We then focus on 3 clinical arenas in which cutaneous alloimmunity is most visible: classic skin-graft rejection, rejection of vascularized composite allografts (VCAs), and graft-versus-host disease (GVHD). Across settings, acute injury is T-cell dominated but with different effector cell "provenance." Target selection is likewise patterned rather than random. Basal keratinocytes and epidermal/follicular stem-cell niches may be early victims of cytotoxic and cytokine signals. In parallel, the vasculature emerges as a second critical target. Microvascular injury may accompany epithelial targeting in skin-graft and acute-VCA rejection, whereas chronic VCA rejection also shows macrovascular injury akin to inflammatory stages of arteriosclerosis culminating in dermal sclerosis with chronicity with similarities to chronic GVHD and scleroderma. Thus, many of these endpoints of various forms of alloreactivity mirror changes seen in "endogenous" dermatoses-fixed drug eruption for acute interface lesions and lupus/scleroderma for chronic fibrosing change-potentially revealing shared downstream pathways despite distinct triggers. We also highlight practical implications: site-oriented surveillance (notably oral/nasal mucosal biopsies that can outperform external skin early in VCA rejection), emerging tissue and circulating biomarkers, and therapeutic directions that pair immune regulation with tissue protection. Drawn from hundreds of biopsies across experimental models, skin allografts, VCAs, and GVHD, the unifying message is that who the effectors are (host vs donor), where they strike (stem-cell niches vs vasculature), and how those injuries unfold over time determine whether skin heals, scars, or fails-hopefully clarifying mechanisms and guiding more precise, tolerance-leaning, fibrosis-sparing care.